Brian A Lanman

Years Active: 2019-2022
Publications (10 Years): 2

Amgen Inc

Harvard University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Amgen Inc

United States

Principal Scientist :: Department of Medicinal Chemistry

Education History

Harvard University

United States

PHD :: Chemistry

Publications

Brian A Lanman, Andrew T Parsons, Stephan G Zech
Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations. Accounts of chemical research 55 (20) (2022)
Brian A Lanman, Jennifer R Allen, John G Allen, Albert K Amegadzie, Kate S Ashton, Shon K Booker, Jian Jeffrey Chen, Ning Chen, Michael J Frohn, Guy Goodman, David J Kopecky, Longbin Liu, Patricia Lopez, Jonathan D Low, Vu Ma, Ana E Minatti, Thomas T Nguyen, Nobuko Nishimura, Alexander J Pickrell, Anthony B Reed, Youngsook Shin, Aaron C Siegmund, Nuria A Tamayo, Christopher M Tegley, Mary C Walton, Hui-Ling Wang, Ryan P Wurz, May Xue, Kevin C Yang, Pragathi Achanta, Michael D Bartberger, Jude Canon, L Steven Hollis, John D McCarter, Christopher Mohr, Karen Rex, Anne Y Saiki, Tisha San Miguel, Laurie P Volak, Kevin H Wang, Douglas A Whittington, Stephan G Zech, J Russell Lipford, Victor J Cee
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors. Journal of medicinal chemistry 63 (1) (2019)

Brian A Lanman.css-eqlu8i{font-size:small;padding-left:4px;}